Therapy for Severe Psoriasis
Seiten
2017
Elsevier - Health Sciences Division (Verlag)
978-0-323-44797-3 (ISBN)
Elsevier - Health Sciences Division (Verlag)
978-0-323-44797-3 (ISBN)
A brand-new title in the field of dermatology, Therapy for Severe Psoriasis provides the ultimate coverage of the treatment options available for today's most serious cases, including biologics and oral therapies. It features discussions of the newest drug therapies, recent FDA-approved biosimilars, and combination approaches to care, while an overview chapter was designed to aid those new to the field in understanding the nuances of difficult-to-treat subtypes of psoriasis. Comprehensive and focused, Therapy for Severe Psoriasis will be a welcome addition to the library of any dermatologist seeking in-depth information on the challenges of this condition.
Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab.
Takes an evidence-based approach to hard-to-treat severe psoriasis.
Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text.
Presents combination approaches for instances when standard treatments are not successful.
Includes an overview chapter to help beginners understand the nuances of the disorder.
Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, images, and references from the book on a variety of devices.
Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab.
Takes an evidence-based approach to hard-to-treat severe psoriasis.
Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text.
Presents combination approaches for instances when standard treatments are not successful.
Includes an overview chapter to help beginners understand the nuances of the disorder.
Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, images, and references from the book on a variety of devices.
Mark G. Lebwohl, MD, FAAD Chairman Emeritus Kimberly and Eric J. Waldman Department of Dermatology Dean for Clinical Therapeutics Icahn School of Medicine at Mount Sinai New York, NY, USA
Erscheinungsdatum | 11.01.2017 |
---|---|
Verlagsort | Philadelphia |
Sprache | englisch |
Maße | 152 x 229 mm |
Gewicht | 570 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Dermatologie |
ISBN-10 | 0-323-44797-X / 032344797X |
ISBN-13 | 978-0-323-44797-3 / 9780323447973 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Differentialdiagnostik und Therapie bei Kindern und Jugendlichen
Buch (2022)
Thieme (Verlag)
165,00 €
Allergene - Diagnostik - Therapie
Buch (2022)
Thieme (Verlag)
200,00 €
richtig verschreiben – individuell therapieren
Buch (2023)
Thieme (Verlag)
71,00 €